Loading clinical trials...

SSTR2 Imaging With [68Ga]Ga-DOTA-TOC PET/CT in NPC | Clinical Trials | Clareo Health

RECRUITINGPHASE1/PHASE2

SSTR2 Imaging With [68Ga]Ga-DOTA-TOC PET/CT in NPC

Towards Improved Therapy Selection and Targeted Treatment for Nasopharyngeal Carcinoma: a Proof-of-concept Pilot Study for Somatostatin Receptor 2 Imaging With [68Ga]Ga-DOTA-TOC PET/CT.

NCT06982300•University Medical Center Groningen

View on ClinicalTrials.gov

Summary

This is an investigator-initiated, single-center clinical trial designed to evaluate the feasibility of \[68Ga\]Ga-DOTA-TOC positron emission tomography (PET) scan in patients with Epstein-Barr virus (EBV) related nasopharyngeal carcinome (NPC) prior to and three weeks after the start of induction chemotherapy or concurrent chemoradiotherapy (CRT). Archival tumor tissue from the diagnostic biopsy will be used to perform somatostatin receptor 2 (SSTR2) immunohistochemistry (IHC). Blood samples will be drawn at baseline, after three weeks, after completion of induction chemotherapy if applicable, and after CRT.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Stage IB-IVA NPC (AJCC 9th edition), EBV positive determined by Epstein-Barr virus-encoded RNA (EBER).
•Planned treatment with induction chemotherapy or CRT without induction chemotherapy.
•Age ≥ 18 years.
•Signed informed consent.
•Willingness and ability to comply with all protocol required procedures.
•Negative serum pregnancy test at screening in women of childbearing potential.
•Archival tumor tissue available or consent to undergo a tumor biopsy procedure.

Exclusion Criteria

•Previous treatment with chemotherapy or radiotherapy for NPC.
•Treatment with any investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to \[68Ga\]Ga-DOTA-TOC injection.
•Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or that may affect the interpretation of the results or render the patient at high risk from complications.
•Altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.
•Inability to lie in supine position for 25 minutes.
•Patients who are pregnant or breastfeeding.

Locations (1)

University Medical Center Groningen

Groningen, Netherlands

Key Dates

Start Date

September 25, 2025

Primary Completion Date

December 1, 2026

Completion Date

December 1, 2026

Last Updated

October 3, 2025

Enrollment

ESTIMATED participants

Conditions

Nasopharyngeal Carcinoma (NPC)

Interventions

[68Ga]Ga-DOTA-TOC PET imaging

OTHER

Contacts

Sjoukje F. Oosting, MD, PhD

CONTACT

+31 50 3612821 s.oosting@umcg.nl

Fleur van Doorn, MD

CONTACT

+31 50 361 2821 f.l.van.doorn@umcg.nl

Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial

NCT07340515

Nasopharyngeal Carcinoma (NPC)

View study

RECRUITINGPHASE2

Effect of Nutritional Management on Patients With Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma

NCT07085988

Nasopharyngeal Carcinoma (NPC)

View study

RECRUITINGNA

Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 3, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

SSTR2 Imaging With [68Ga]Ga-DOTA-TOC PET/CT in NPC

Inclusion Criteria

Exclusion Criteria

Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial

Effect of Nutritional Management on Patients With Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma

Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas

Molecular Research on Predictive Efficacy and New Therapeutic Targets for Nasopharyngeal Carcinoma